Kovler Diabetes Center Research Studies

UChicago Medicine is participating in a phase 2 clinical trial, sponsored by Amgen, Inc. This study will assess the effectiveness, safety and tolerability of a potential new anti-obesity medication in adult participants with overweight or obesity, with or without Type 2 Diabetes Mellitus.

The Multicenter Assessment of the Pancreas in Type 1 Diabetes (MAP-T1D) is an international team of researchers that focus on using magnetic resonance imaging (MRI) to investigate changes in pancreas volume and microarchitecture in individuals with diabetes. Center Director Louis Philipson, MD, PhD, and Siri Atma Greeley, MD, PhD, are the principal investigators at UChicago Medicine for the MAP-T1D project.

Contact Demetra Braun at Demetra.Braun@bsd.uchicago.edu or visit https://www.map-t1d.com/ for more information.

UChicago Medicine is participating in a phase 3 clinical trial. This study will see how a weekly insulin helps in reducing the blood sugar compared to daily insulin, both in combination with rapid-acting insulin, in adults with Type 1 Diabetes.

For more information about the study and to learn if you may be eligible, please contact Demetra Braun at Demetra.Braun@bsd.uchicago.edu or 773-702-4802.

The Rare and Atypical Diabetes Network (RADIANT) trial, for which Center Director Louis Philipson, MD, PhD, and Siri Atma Greeley, MD, PhD, are the principal investigators, is discovering and defining rare and atypical forms of diabetes, a signature project of the Kovler Diabetes Center.

RADIANT is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). RADIANT is a network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Our team of academic institutions and scientists collaborate with physicians and healthcare groups to identify people with atypical diabetes and learn more about their health.

Contact Ava Jerred, at ava.jerred@bsd.uchicago.edu or visit https://www.atypicaldiabetesnetwork.org/ for more information.

UChicago Medicine is participating in a phase 2 clinical trial, sponsored by Indiana University. This study will assess the effectiveness, safety, and tolerability of Difluoromethylornithine (DFMO) to preserve insulin production in people living with type 1 diabetes.

For more information about the study and to learn if you may be eligible, please contact Cathleen Mulcahy at 773-702-9968 or visit https://clinicaltrials.gov/study/NCT05594563.

The overall objective of this study is to perform baseline and repeat assessments over time of the metabolic and immunologic status of individuals at risk for T1D in order to:

• Characterize their risk for developing T1D
• Describe the pathogenetic evolution of T1D
• Increase the understanding of the pathogenetic factors involved in the development of T1D

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in subjects who Have Type 1 Diabetes Mellitus with impaired Hypoglycemic Awareness and the following:

• Severe Hypoglycemia for Clinical Islet Transplantation Population: Ages 18-65
• Clinical history of T1D with > 5 years of duration
• Consistent use of continuous glucose monitor (CGM)

Contact: Hannah Gilkey: Hannah.Gilkey@bsd.uchicago.edu

The purpose of this study is to assess the safety and effectiveness of the study drug ZT-01 on the occurrence of nighttime hypoglycemia. Potential subjects must meet the following eligibility requirements:

• Diagnosed with Type 1 Diabetes Mellitus on multiple daily injections (MDI) or insulin pump
• Age 18-75
• At risk of nocturnal hypoglycemia